{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:04:30Z","timestamp":1785326670556,"version":"3.55.0"},"reference-count":38,"publisher":"Akademiai Kiado Zrt.","issue":"8","license":[{"start":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T00:00:00Z","timestamp":1708819200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2024,2,25]]},"abstract":"<jats:p>A szepszis az orvostudom\u00e1ny fejl\u0151d\u00e9se ellen\u00e9re tov\u00e1bbra is relev\u00e1ns, komplex\n                    k\u00f3rk\u00e9p, mely szeptikus sokkba kibontakozva jelent\u0151s mortalit\u00e1ssal j\u00e1r. A\n                    szeptikus sokk egyik jellemz\u0151je a vasodilatati\u00f3val, hypotensi\u00f3val \u00e9s nem\n                    megfelel\u0151 sz\u00f6veti perf\u00fazi\u00f3val jellemezhet\u0151 hemodinamikai instabilit\u00e1s. A\n                    hagyom\u00e1nyosan, folyad\u00e9kresuscitati\u00f3t \u00e9s katecholamin vazopresszorokat alkalmaz\u00f3\n                    ell\u00e1t\u00e1s gyakran nem k\u00e9pes helyre\u00e1ll\u00edtani a megfelel\u0151 perf\u00fazi\u00f3t \u00e9s jav\u00edtani a\n                    kimenetelt. K\u00f6vetkez\u00e9sk\u00e9ppen egyre nagyobb \u00e9rdekl\u0151d\u00e9s mutatkozik az alternat\u00edv\n                    vazoakt\u00edv szerek felt\u00e1r\u00e1sa ir\u00e1nt. Az egyik ilyen szer a vazopresszin, mely\n                    \u00edg\u00e9retes kieg\u00e9sz\u00edt\u0151nek bizonyult a szeptikus sokk kezel\u00e9s\u00e9ben. A szeptikus\n                    sokkban a vazopresszin hat\u00e9konys\u00e1g\u00e1t \u00e9s biztons\u00e1goss\u00e1g\u00e1t tanulm\u00e1nyoz\u00f3 klinikai\n                    vizsg\u00e1latok elt\u00e9r\u0151 eredm\u00e9nyeket hoztak, ami folyamatos vit\u00e1t \u00e9s tov\u00e1bbi\n                    vizsg\u00e1latokat v\u00e1ltott ki. Alkalmaz\u00e1s\u00e1ban egyel\u0151re nincs egy\u00f6ntet\u0171 konszenzus.\n                    Sz\u00e1mos randomiz\u00e1lt, kontroll\u00e1lt vizsg\u00e1lat \u00e9rt\u00e9kelte a vazopresszin alkalmaz\u00e1s\u00e1t\n                    a hagyom\u00e1nyos ter\u00e1pia kieg\u00e9sz\u00edt\u00e9sek\u00e9nt, \u00e9s olyan lehets\u00e9ges el\u0151ny\u00f6ket mutattak\n                    ki, mint a hemodinamikai stabilit\u00e1s javul\u00e1sa \u00e9s az enyh\u00e9bb szeptikus betegek\n                    eset\u00e9ben a mortalit\u00e1s cs\u00f6kkent\u00e9se. Az ellentmond\u00e1sos eredm\u00e9nyek \u00e9s a\n                    nemk\u00edv\u00e1natos esem\u00e9nyekkel, k\u00f6zt\u00fck az ischaemi\u00e1s sz\u00f6v\u0151dm\u00e9nyekkel kapcsolatos\n                    agg\u00e1lyok azonban sz\u00fcks\u00e9gess\u00e9 teszik az optim\u00e1lis adagol\u00e1s, id\u0151z\u00edt\u00e9s \u00e9s a\n                    megfelel\u0151 betegszelekci\u00f3 \u00e1tfog\u00f3 meg\u00e9rt\u00e9s\u00e9t. \u00d6sszefoglal\u00f3 k\u00f6zlem\u00e9ny\u00fcnk c\u00e9lja,\n                    hogy \u00e1tfog\u00f3 \u00e1ttekint\u00e9st adjon a vazopresszinr\u0151l \u00e9s haszn\u00e1lat\u00e1r\u00f3l a szeptikus\n                    sokk ell\u00e1t\u00e1s\u00e1ban. \u00d6sszefoglalja a klinikai vizsg\u00e1latokb\u00f3l sz\u00e1rmaz\u00f3 jelenlegi\n                    eredm\u00e9nyeket, miszerint a vazopresszin-ter\u00e1pia k\u00f6lts\u00e9ghat\u00e9kony kieg\u00e9sz\u00edt\u0151\n                    vazopresszor a noradrenalinter\u00e1pia mell\u00e9. Hat\u00e9konyan cs\u00f6kkenti a betegek\n                    katecholamin-ig\u00e9ny\u00e9t, cs\u00f6kkentheti a vesep\u00f3tl\u00f3 kezel\u00e9sek sz\u00fcks\u00e9gess\u00e9g\u00e9t \u00e9s az \u00faj\n                    arrhythmi\u00e1k el\u0151fordul\u00e1s\u00e1t, de a sokszor ellentmond\u00e1sos vagy biztons\u00e1ggal nem\n                    reproduk\u00e1lhat\u00f3 vizsg\u00e1lati eredm\u00e9nyek miatt jelenleg er\u0151s evidencia hi\u00e1ny\u00e1ban\n                    m\u00e1sodvonalbeli szerk\u00e9nt aj\u00e1nlj\u00e1k. Orv Hetil. 2024; 165(8): 283\u2013290.<\/jats:p>","DOI":"10.1556\/650.2024.32992","type":"journal-article","created":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T03:48:05Z","timestamp":1709437685000},"page":"283-290","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["Vazopresszin haszn\u00e1lata szeptikus sokkos betegek ell\u00e1t\u00e1s\u00e1ban"],"prefix":"10.1556","volume":"165","author":[{"given":"Endre","family":"Hajdu","sequence":"first","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Aneszteziol\u00f3giai \u00e9s Intenz\u00edv Ter\u00e1pi\u00e1s Klinika Debrecen, Nagyerdei krt. 22., 4032 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariann","family":"Berh\u00e9s","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Aneszteziol\u00f3giai \u00e9s Intenz\u00edv Ter\u00e1pi\u00e1s Klinika Debrecen, Nagyerdei krt. 22., 4032 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"L\u00e1szl\u00f3","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Aneszteziol\u00f3giai \u00e9s Intenz\u00edv Ter\u00e1pi\u00e1s Klinika Debrecen, Nagyerdei krt. 22., 4032 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Ol\u00e1h","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Aneszteziol\u00f3giai \u00e9s Intenz\u00edv Ter\u00e1pi\u00e1s Klinika Debrecen, Nagyerdei krt. 22., 4032 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"F\u00fclesdi","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Aneszteziol\u00f3giai \u00e9s Intenz\u00edv Ter\u00e1pi\u00e1s Klinika Debrecen, Nagyerdei krt. 22., 4032 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Asztalos","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Aneszteziol\u00f3giai \u00e9s Intenz\u00edv Ter\u00e1pi\u00e1s Klinika Debrecen, Nagyerdei krt. 22., 4032 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"K\u00f3ph\u00e1zi LK, K\u00e1rp\u00e1thi IK, Keszty\u0171s V, et al. Challenge in modern\n                    intensive care: chronic critical illness \u2013 pathophysiology and therapeutic\n                    options. [A modern intenz\u00edv ter\u00e1pia kih\u00edv\u00e1sa: az elh\u00faz\u00f3d\u00f3 kritikus \u00e1llapot\n                    k\u00f3r\u00e9lettani h\u00e1ttere \u00e9s ter\u00e1pi\u00e1s lehet\u0151s\u00e9gei.] Orv Hetil. 2023; 164: 702\u2013712.\n                    [Hungarian]","DOI":"10.1556\/650.2023.32745"},{"key":"R2","unstructured":"Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign:\n                    international guidelines for management of sepsis and septic shock 2021. Crit\n                    Care Med. 2021; 49: e1063\u2013e1143."},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Ince C. The microcirculation is the motor of sepsis. Crit Care 2005;\n                    9(Suppl 4): S13\u2013S19.","DOI":"10.1186\/cc3753"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Holmes CL, Patel BM, Russel JA, et al. Physiology of vasopressin\n                    relevant to management of septic shock. Chest 2001; 120:\n                    989\u20131002.","DOI":"10.1378\/chest.120.3.989"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Radics P, Kiss B, Kov\u00e1cs E, et al. The application of landiolol in\n                    the cardiovascular and intensive care. [A landiolol alkalmaz\u00e1si lehet\u0151s\u00e9gei a\n                    kardiol\u00f3giai \u00e9s intenz\u00edv ter\u00e1pi\u00e1s ell\u00e1t\u00e1sban.] Orv Hetil. 2022; 163: 53\u201362.\n                    [Hungarian]","DOI":"10.1556\/650.2022.32347"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of\n                    short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;\n                    96: 576\u2013582.","DOI":"10.1097\/00000542-200203000-00011"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Knotzer H, Maier S, D\u00fcnser MW, et al. Arginine vasopressin does not\n                    alter mucosal tissue oxygen tension and oxygen supply in an acute endotoxemic\n                    pig model. Intensive Care Med. 2006; 32: 170\u2013174.","DOI":"10.1007\/s00134-005-2858-z"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Maier S, Hasibeder W, Pajk W, et al. Arginine-vasopressin attenuates\n                    beneficial norepinephrine effect on jejunal mucosal tissue oxygenation during\n                    endotoxinaemia. Br J Anaesth. 2009; 103: 691\u2013700.","DOI":"10.1093\/bja\/aep239"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Huch KM, Runyan KR, Wall BM, et al. Hemodynamic response to\n                    vasopressin during V1-receptor antagonism in baroreflex-deficient subjects. Am J\n                    Physiol. 1995; 268: R156\u2013R163.","DOI":"10.1152\/ajpregu.1995.268.1.R156"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Ji MH, Yang JJ, Wu J, et al. Experimental sepsis in pigs \u2013 effects\n                    of vasopressin on renal, hepatic, and intestinal dysfunction. Ups J Med Sci.\n                    2012; 117: 257\u2013263.","DOI":"10.3109\/03009734.2011.650796"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Holmes CL , Walley KR, Chittock DR, et al. The effects of\n                    vasopressin on hemodynamics and renal function in severe septic shock: a case\n                    series. Intensive Care Med. 2001; 27: 1416\u20131421.","DOI":"10.1007\/s001340101014"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Klinzing S, Simon M, Reinhart K, et al. High-dose vasopressin is not\n                    superior to norepinephrine in septic shock. Crit Care Med. 2003; 31:\n                    2646\u20132650.","DOI":"10.1097\/01.CCM.0000094260.05266.F4"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic\n                    effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit\n                    Care Med. 2001; 29: 487\u2013493.","DOI":"10.1097\/00003246-200103000-00004"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor\n                    hypersensitivity in vasodilatory septic shock. Crit Care Med. 1997; 25:\n                    1279\u20131282.","DOI":"10.1097\/00003246-199708000-00012"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Russell JA, Walley KR, Singer J, et al. Vasopressin versus\n                    norepinephrine infusion in patients with septic shock. N Engl J Med. 2008; 358:\n                    877\u2013887.","DOI":"10.1056\/NEJMoa067373"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early\n                    vasopressin vs norepinephrine on kidney failure in patients with septic shock:\n                    the VANISH randomized clinical trial. JAMA 2016; 316: 509\u2013518.","DOI":"10.1001\/jama.2016.10485"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, et al. Vasopressin\n                    versus norepinephrine in patients with vasoplegic shock after cardiac surgery:\n                    the VANCS randomized controlled trial. Anesthesiology 2017; 126:\n                    85\u201393.","DOI":"10.1097\/ALN.0000000000001543"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Torgersen C, D\u00fcnser MW, Wenzel V, et al. Comparing two different\n                    arginine vasopressin doses in advanced vasodilatory shock: a randomized,\n                    controlled, open-label trial. Intensive Care Med. 2010; 36:\n                    57\u201365.","DOI":"10.1007\/s00134-009-1630-1"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Luckner G, Mayr VD, Jochberger S, et al. Comparison of two dose\n                    regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med.\n                    2007; 35: 2280\u20132285.","DOI":"10.1097\/01.CCM.0000281853.50661.23"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Torgersen C, Luckner G, Schr\u00f6der DC, et al. Concomitant\n                    arginine-vasopressin and hydrocortisone therapy in severe septic shock:\n                    association with mortality. Intensive Care Med. 2011; 37:\n                    1432\u20131437.","DOI":"10.1007\/s00134-011-2312-3"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Bauer SR, Lam SW, Cha SS, et al. Effect of corticosteroids on\n                    arginine vasopressin-containing vasopressor therapy for septic shock: a case\n                    control study. J Crit Care 2008; 23: 500\u2013506.","DOI":"10.1016\/j.jcrc.2008.04.002"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"McIntyre WF, Um KJ, Alhazzani W, et al. Association of vasopressin\n                    plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation\n                    in patients with distributive shock: a systematic review and meta-analysis. JAMA\n                    2018; 319: 1889\u20131900.","DOI":"10.1001\/jama.2018.4528"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Hajjar LA, Zambolim C, Belletti A, et al. Vasopressin versus\n                    norepinephrine for the management of septic shock in cancer patients: the VANCS\n                    II randomized clinical trial. Crit Care Med. 2019; 47:\n                    1743\u20131750.","DOI":"10.1097\/CCM.0000000000004023"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Oba Y, Lone NA. Mortality benefit of vasopressor and inotropic\n                    agents in septic shock: a Bayesian network meta-analysis of randomized\n                    controlled trials. J Crit Care 2014; 29: 706\u2013710.","DOI":"10.1016\/j.jcrc.2014.04.011"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"D\u00fcnser MW, Mayr AJ, T\u00fcr A, et al. Ischemic skin lesions as a\n                    complication of continuous vasopressin infusion in catecholamine-resistant\n                    vasodilatory shock: incidence and risk factors. Crit Care Med. 2003; 31:\n                    1394\u20131398.","DOI":"10.1097\/01.CCM.0000059722.94182.79"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Czaczkes JW, Kleeman CR, Koenig M, et al. Physiologic studies of\n                    antidiuretic hormone by its direct measurement in human plasma. J Clin Invest.\n                    1964; 43: 1625\u20131640.","DOI":"10.1172\/JCI105038"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Nakamura K, Nakano H, Naraba H, et al. Vasopressin loading for\n                    refractory septic shock: a preliminary analysis of a case series. Front Med.\n                    2021; 8: 644195","DOI":"10.3389\/fmed.2021.644195"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Nakamura K, Nakano H, Ikechi D, et al. The vasopressin loading for\n                    refractory septic shock (VALOR) study: a prospective observational study. Crit\n                    Care 2023; 27: 294.","DOI":"10.1186\/s13054-023-04583-7"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Russell JA, Walley KR, Gordon AC, et al. Interaction of vasopressin\n                    infusion, corticosteroid treatment, and mortality of septic shock. Crit Care\n                    Med. 2009; 37: 811\u2013818.","DOI":"10.1097\/CCM.0b013e3181961ace"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Pietranera L, Saravia F, Roig P, et al. Mineralocorticoid treatment\n                    upregulates the hypothalamic vasopressinergic system of spontaneously\n                    hypertensive rats. Neuroendocrinology 2004; 80: 100\u2013110.","DOI":"10.1159\/000081314"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Ertmer C, Bone HG, Morelli A, et al. Methylprednisolone reverses\n                    vasopressin hyporesponsiveness in ovine endotoxemia. Shock 2007; 27:\n                    281\u2013288.","DOI":"10.1097\/01.shk.0000235140.97903.90"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Dugar S, Siuba MT, Sacha GL, et al. Echocardiographic profiles and\n                    hemodynamic response after vasopressin initiation in septic shock: a\n                    cross-sectional study. J Crit Care 2023; 76: 154298.","DOI":"10.1016\/j.jcrc.2023.154298"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Reardon DP, DeGrado JR, Anger KE, et al. Early vasopressin reduces\n                    incidence of new onset arrhythmias. J Crit Care 2014; 29:\n                    482\u2013485.","DOI":"10.1016\/j.jcrc.2014.03.005"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Hammond DA, Sacha GL, Bissell BD, et al. Effects of norepinephrine\n                    and vasopressin discontinuation order in the recovery phase of septic shock: a\n                    systematic review and individual patient data meta-analysis. Pharmacotherapy\n                    2019; 39: 544\u2013552.","DOI":"10.1002\/phar.2265"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Sacha GL, Lam SW, Duggal A, et al. Hypotension risk based on\n                    vasoactive agent discontinuation order in patients in the recovery phase of\n                    septic shock. Pharmacotherapy 2018; 38: 319\u2013326.","DOI":"10.1002\/phar.2082"},{"key":"R36","unstructured":"Csom\u00f3s \u00c1, Hoffer G, F\u00fclesdi B, et al. The incidence and cost of\n                    severe sepsis in intensive care units. [A s\u00falyos szepszis gyakoris\u00e1ga \u00e9s\n                    kezel\u00e9s\u00e9nek k\u00f6lts\u00e9ge intenz\u00edv oszt\u00e1lyon.] Orv Hetil. 2005; 146: 1543\u20131547.\n                    [Hungarian]"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Bauer SR, Sacha GL, Reddy AJ. Mortality, morbidity, and costs after\n                    implementation of a vasopressin guideline in medical intensive care patients\n                    with septic shock: an interrupted time series analysis. Ann Pharmacother. 2020;\n                    54: 314\u2013321.","DOI":"10.1177\/1060028019886306"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Lam SW, Barreto EF, Scott R, et al. Cost-effectiveness of\n                    second-line vasopressors for the treatment of septic shock. J Crit Care 2020;\n                    55: 48\u201355.","DOI":"10.1016\/j.jcrc.2019.10.005"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/165\/8\/article-p283.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/165\/8\/article-p283.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/165\/8\/article-p283.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:16:02Z","timestamp":1785323762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/165\/8\/article-p283.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,25]]},"references-count":38,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.1556\/650.2024.32992","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,25]]}}}